Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation

International Journal of Laboratory Hematology

Volumn 31, Issue 2, 2009, Pages 161-168

  Toubai, T ^a,b,c   Shono, Y ^b   Nishihira, J ^d   Ibata, M ^b   Suigita, J ^b   Kato, N ^b   Ohkawara, T ^d   Tone, S ^d   Lowler, K P ^c   Ota, S ^b   Tanaka, J ^b   Asaka, M ^b   Reddy, P ^c   Imamura, M ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d GeneticLab Co Ltd   (Japan)

Author keywords

Acute graft versus host disease; Allogeneic stem cell transplantation; Chronic graft versus host disease; Macrophage migration inhibitory factor

Indexed keywords

CYCLOSPORIN; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD LEVEL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MACROPHAGE MIGRATION; MALE; PATHOGENICITY; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 61349156249     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.01016.x     Document Type: Article

References (32)

1. Asif Amin M., Haas C.H., Zhu K., Mansfield P.J., Kim M.J., Lackowski N.P. Koch A.E. (2006) Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 linase, and NFkB. Blood 107, 2252 2261.
2. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., Gemsa D., Donnelly T. Bucala R. (1996) An essential regulatory role for macrophage migration inhibitory factor in T cell activation. Proceedings of the National Academy of Sciences of the United States of America 93, 7849 7854.
3. Baker K.S., Gurney J.G., Ness K.K., Bhatia R., Forman S.J., Francisco L., McGlave P.B., Robison L.L., Snyder D.S., Weisdorf D.J. Bhatia S. (2004) Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 104, 1898 1906.
4. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., Manogue K.R., Cerami A. Bucala R. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756 759.
5. Bernhagen J., Bacher M., Calandra T., Metz C.N., Doty S.B., Donnelly T. Bucala R. (1996) An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. The Journal of Experimental Medicine 183, 277 282.
6. Bloom B.R. Bennett B. (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80 82.
7. Brown F.G., Nikolic-Paterson D.J., Metz C., Bucala R., Atkins R.C. Lan H.Y. (1999) Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clinical and Experimental Immunology 118, 329 336.
8. Bucala R. (1996) MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. The FASEB Journal 10, 1607 1613.
9. Calandra T., Bernhagen J., Mitchell R.A. Bucala R. (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. The Journal of Experimental Medicine 179, 1895 1902.
10. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., Cerami A. Bucala R. (1995) MIF as a glucocorticoid-induces modulator of cytokine production. Nature 377, 68 71.
11. David J.R. (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences of the United States of America 56, 72 77.
12. Donnelly S.C., Haslett C., Reid P.T., Grant I.S., Wallace W.A., Metz C.N., Bruce L.J. Bucala R. (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine 3, 320 323.
13. Ferrara J.L., Cooke K.R. Teshima T. (2003) The pathophysiology of acute graft-versus-host disease. International Journal of Hematology 78, 181 187.
14. Ferrara J.L. Deeg H.J. (1991) Graft-versus-host disease. New England Journal of Medicine 324, 667 674.
15. Graze P.R. Gale R.P. (1979) Chronic graft versus host disease: a syndrome of disordered immunity. The American Journal of Medicine 66, 611 620.
16. Hill G.R. Ferrara J.L. (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus- host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95, 2754 2759.
17. de Jong Y.P., Abadia-Molina A.C., Satoskar A.R., Clarke K., Rietdijk S.T., Faubion W.A., Mizoguchi E., Metz C.N., Alsahli M., ten Hove T., Keates A.C., Lubetsky J.B., Farrell R.J., Michetti P., van Deventer S.J., Lolis E., David J.R., Bhan A.K. Terhorst C. (2001) Development of chronic colitis is dependent on the cytokine MIF. Nature Immunology 2, 1061 1066.
18. Jose M.D., David J.R., Atkins R.C. Chadban S.J. (2003) Blockade of macrophage migration inhibitory factor does not prevent acute renal allograft rejection. American Journal of Transplantation 3, 1099 1106.
19. Lan H.Y., Bacher M., Yang N., Mu W., Nikolic-Paterson D.J., Metz C., Meinhardt A., Bucala R. Atkins R.C. (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. The Journal of Experimental Medicine 185, 1455 1465.
20. Lan H.Y., Yang N., Brown F.G., Isbel N.M., Nikolic-Paterson D.J., Mu W., Metz C.N., Bacher M., Atkins R.C. Bucala R. (1998) Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 66, 1465 1471.
21. Lan H.Y., Yang N., Nikolic-Paterson D.J., Yu X.Q., Mu W., Isbel N.M., Metz C.N., Bucala R. Atkins R.C. (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney International 57, 499 509.
22. Lo J.W., Leung A.Y., Huang X.R., Lie A.K., Metz C., Bucala R., Liang R. Lan H.Y. (2002) Macrophage migration inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 30, 375 380.
23. Matsumoto K., Maruyama N., Maruyama T., Ohnishi Y., Nonaka S., Inoshita A., Ito K., Kitajima S., Abe M., Satomura A. Fujita T. (2005) Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis. Clinical and Experimental Immunology 139, 338 347.
24. Nishihira J. (2000) Macrophage migrataion inhibitory factor (MIF): its essential role in the immune system and cell growth. Journal of Interferon and Cytokine Research 20, 751 762.
25. Ohkawara T., Nishihira J., Takeda H., Hige S., Kato M., Sugiyama T., Iwanaga T., Nakamura H., Mizue Y. Asaka M. (2002) Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123, 256 270.
26. Onodera S., Tanji H., Suzuki K., Kaneda K., Mizue Y., Sagawa A. Nishihira J. (1999) High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11, 163 167.
27. Reddy P. Ferrara J.L. (2003) Immunobiology of acute graft-versus-host disease. Blood Reviews 17, 187 194.
28. Selvi E., Tripodi S.A., Catenaccio M., Lorenzini S., Chindamo D., Manganelli S., Romagnoli R., Ietta F., Paulesu L., Miracco C., Cintorino M. Marcolongo R. (2003) Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Annals of the Rheumatic Diseases 62, 460 464.
29. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., Shlomchik M.J. Emerson S.G. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412 415.
30. Shulman H.M., Sullivan K.M., Weiden P.L., McDonald G.B., Striker G.E., Sale G.E., Hackman R., Tsoi M.S., Storb R. Thomas E.D. (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. The American Journal of Medicine 69, 204 217.
31. Socie G., Stone J.V., Wingard J.R., Weisdorf D., Henslee-Downey P.J., Bredeson C., Cahn J.Y., Passweg J.R., Rowlings P.A., Schouten H.C., Kolb H.J. Klein J.P. (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. New England Journal of Medicine 341, 14 21.
32. Toubai T., Tanaka J., Nishihira J., Ohkawara T., Hirate D., Kondo N., Tone S., Shono Y., Ibata M., Sugita J., Kato N., Miura Y., Iwao N., Ota S. Imamura M. (2006) Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation. Transplant immunology 16, 117 124.